Novartis builds cancer pipeline with a new platform/drug buyout, bagging Advanced Accelerator Applications for $3.9B
Novartis has just bought itself a new cancer therapy as well as a new tech platform for $3.9 billion in cash, bagging the French biotech …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.